tradingkey.logo

Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026

ReutersMar 1, 2026 5:31 PM

- Rhythm Pharmaceuticals Inc RYTM.O:

  • RHYTHM PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 3 TRANSCEND TRIAL OF SETMELANOTIDE IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY

  • RHYTHM PHARMACEUTICALS INC - PDUFA GOAL DATE FOR SETMELANOTIDE IS MARCH 20, 2026

  • RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH 16.4% BMI REDUCTION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI